Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00484536 · ClinicalTrials.gov registry record · Phase 2
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
A Phase 2 study, sponsored by UCB Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 232
- Enrollment target
NCT00484536: Clinical Trial Phase 2 study, sponsored by UCB Pharma.
NCT00484536 is a Phase 2 study that was terminated before completion, run by UCB Pharma. The registered enrollment target is 232 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00484536, a Phase 2 study, was terminated before completion, sponsored by UCB Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 232 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis
Primary Outcome
The following lesions are considered newly active: new gadolinium enhancement on T1-weighted images; new lesions on T2-weighted images, but non-enhancing on T1-weighted images; new enlargement on T2-weighted images, but non-enhancing on T1-weighted images.
Interventions
- DRUG placebo
- DRUG CDP323
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Why NCT00484536 stopped before completion
NCT00484536 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00484536 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00484536 about?
NCT00484536 is a clinical study titled "Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323". The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis
What is the current status of trial NCT00484536?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 232 participants. The study started on 2007-05. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00484536?
The interventions under investigation include: placebo (DRUG), CDP323 (DRUG).
Who is sponsoring clinical trial NCT00484536?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00484536's enrollment target sits among peer trials
232 256th of 2000 higher than 1,744 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia